RA0366

antibody from Oursmab
Targeting: IL23A IL-23, IL-23A, IL23P19, P19, SGRF
Provider product page for RA0366
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0366 - Provider product page
Provider
Oursmab
Product name
Guselkumab (Biosimilar Reference Antibody) (IL23A)
Antibody type
Monoclonal
Description
Guselkumab is a fully human monoclonal IgG1¦Ë antibody approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and moderate-to-severe hidradenitis suppurativa (HS). It functions as a selective interleukin-23 (IL-23) inhibitor. By binding with high affinity to the p19 subunit of IL-23, guselkumab prevents the cytokine from interacting with its receptor complex on the surface of immune cells. This blockade inhibits the IL-23 signaling pathway, which is central to the differentiation, expansion, and survival of pathogenic T helper 17 (Th17) cells. By targeting this upstream cytokine, guselkumab reduces the downstream production of pro-inflammatory mediators (like IL-17, IL-22) that drive inflammation, keratinocyte hyperproliferation, and tissue damage in these conditions.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
IL23A protein structure - RA0366 shown in red.